Biointron Biologics Files for Public Offering, Aims for BSE Listing
On February 11, Biointron Biologics released its tutoring filing report for the public offering of...
Biointron Biologics
Biointron Raises USD 72M in Series B to Expand CRO Services and Antibody Platform
Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500...